Identifying Novel Targets for NAFLD and NASH

Robert Poolman, PhD. MBA
Head of Preclinical Segment, Life Sciences
Clarivate Analytics
Carolyn Finch
Solution Scientist, Team Lead - Life Sciences
Clarivate Analytics

Non-alcoholic fatty liver disease (NAFLD) and its more aggressive form, non-alcoholic steatohepatitis (NASH), have emerged as two of the most prevalent chronic liver diseases in recent years and are projected to be the leading indications for liver transplant within the decade. While there are some treatments for NAFLD, mainly involving lifestyle modifications, there are currently no approved drugs on the market for NASH. This lack of drugs represents a unique opportunity, but the difficulty in identifying druggable targets for this disease has suppressed innovation.

In this webinar, you’ll learn about new tools that are now available to identify and prioritize novel targets for NAFLD and NASH, creating a path for drug developers towards a first-in-class treatment.